Specify Company / Ticker to Get the Summary
Dividend History ETNB
Dividend Analytics ETNB
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–89bio Inc
ETNB89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California. Address: 655 Montgomery Street, San Francisco, CA, United States, 94111
Analytics
WallStreet Target Price
29.45 USDP/E Ratio
–Dividend Yield
–Financials ETNB
Results | 2019 | Dynamics |